Skip to content
2000
Volume 19, Issue 9
  • ISSN: 1570-1808
  • E-ISSN: 1875-628X

Abstract

Background: Narcolepsy, also known as Gélineau syndrome, is a chronic and neurological disease that affects 0.05% of the European population, though that percentage could be higher due to the diagnostic difficulties. The main symptom is excessive daytime sleepiness, although it may be accompanied by cataplexy, sleep paralysis and hypnagogic hallucinations. Objective: Nowadays, there is no cure for narcolepsy, and the treatment is symptomatic; psychostimulants for sleepiness by means of amphetamines, methylphenidate, or modafinil, and antidepressants and sodium oxybate for treating cataplexy. Methods: This is a short review regarding pharmacotherapy for narcolepsy. Results: Hypocretins were discovered in 1998. They are neuropeptides whose deficiency is responsible for this symptomatology, which has opened up a new field of investigation. Conclusion: Agonists of hypocretins could be a promising therapy against this disease.

Loading

Article metrics loading...

/content/journals/lddd/10.2174/1570180819666211227095124
2022-09-01
2025-09-18
Loading full text...

Full text loading...

/content/journals/lddd/10.2174/1570180819666211227095124
Loading

  • Article Type:
    Editorial
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test